Suppr超能文献

线粒体与心血管疾病——从病理生理学到治疗

Mitochondria and cardiovascular diseases-from pathophysiology to treatment.

作者信息

Siasos Gerasimos, Tsigkou Vasiliki, Kosmopoulos Marinos, Theodosiadis Dimosthenis, Simantiris Spyridon, Tagkou Nikoletta Maria, Tsimpiktsioglou Athina, Stampouloglou Panagiota K, Oikonomou Evangelos, Mourouzis Konstantinos, Philippou Anastasios, Vavuranakis Manolis, Stefanadis Christodoulos, Tousoulis Dimitris, Papavassiliou Athanasios G

机构信息

Department of Cardiology, "Hippokration" General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.

Division of Cardiovascular, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

出版信息

Ann Transl Med. 2018 Jun;6(12):256. doi: 10.21037/atm.2018.06.21.

Abstract

Mitochondria are the source of cellular energy production and are present in different types of cells. However, their function is especially important for the heart due to the high demands in energy which is achieved through oxidative phosphorylation. Mitochondria form large networks which regulate metabolism and the optimal function is achieved through the balance between mitochondrial fusion and mitochondrial fission. Moreover, mitochondrial function is upon quality control via the process of mitophagy which removes the damaged organelles. Mitochondrial dysfunction is associated with the development of numerous cardiac diseases such as atherosclerosis, ischemia-reperfusion (I/R) injury, hypertension, diabetes, cardiac hypertrophy and heart failure (HF), due to the uncontrolled production of reactive oxygen species (ROS). Therefore, early control of mitochondrial dysfunction is a crucial step in the therapy of cardiac diseases. A number of anti-oxidant molecules and medications have been used but the results are inconsistent among the studies. Eventually, the aim of future research is to design molecules which selectively target mitochondrial dysfunction and restore the capacity of cellular anti-oxidant enzymes.

摘要

线粒体是细胞能量产生的来源,存在于不同类型的细胞中。然而,由于心脏对能量的高需求(通过氧化磷酸化实现),线粒体的功能对心脏尤为重要。线粒体形成大型网络,调节新陈代谢,而线粒体融合与线粒体分裂之间的平衡可实现其最佳功能。此外,线粒体功能通过线粒体自噬过程进行质量控制,该过程可清除受损细胞器。由于活性氧(ROS)的不受控制产生,线粒体功能障碍与多种心脏疾病的发生有关,如动脉粥样硬化、缺血再灌注(I/R)损伤、高血压、糖尿病、心脏肥大和心力衰竭(HF)。因此,早期控制线粒体功能障碍是心脏病治疗的关键步骤。已经使用了许多抗氧化分子和药物,但研究结果并不一致。最终,未来研究的目标是设计出能够选择性靶向线粒体功能障碍并恢复细胞抗氧化酶能力的分子。

相似文献

2
Mitochondrial biogenesis: pharmacological approaches.线粒体生物合成:药理学方法。
Curr Pharm Des. 2014;20(35):5507-9. doi: 10.2174/138161282035140911142118.
3
4
Mitochondrial quality control in health and cardiovascular diseases.健康与心血管疾病中的线粒体质量控制
Front Cell Dev Biol. 2023 Nov 6;11:1290046. doi: 10.3389/fcell.2023.1290046. eCollection 2023.
6
Mitochondrial dynamics, mitophagy and cardiovascular disease.线粒体动力学、线粒体自噬与心血管疾病
J Physiol. 2016 Feb 1;594(3):509-25. doi: 10.1113/JP271301. Epub 2016 Jan 15.
7
Mitochondrial epigenetics in aging and cardiovascular diseases.衰老与心血管疾病中的线粒体表观遗传学
Front Cardiovasc Med. 2023 Jul 13;10:1204483. doi: 10.3389/fcvm.2023.1204483. eCollection 2023.
10
Mitophagy in cardiovascular disease.心肌自噬与心血管疾病。
Clin Chim Acta. 2020 Aug;507:210-218. doi: 10.1016/j.cca.2020.04.033. Epub 2020 May 1.

引用本文的文献

3
Circulating mitochondrial biomarkers in acute coronary syndrome.急性冠状动脉综合征中的循环线粒体生物标志物
Front Med (Lausanne). 2025 May 15;12:1568305. doi: 10.3389/fmed.2025.1568305. eCollection 2025.

本文引用的文献

8
Statins and inflammation in cardiovascular disease.他汀类药物与心血管疾病中的炎症
Curr Pharm Des. 2017 Oct 9. doi: 10.2174/1381612823666171009141201.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验